unknown
Stage
About
Vigeo is developing a first-in-class drug discovery pipeline that reprograms the tumor microenvironment to enhance immune response against solid tumors, with lead compounds targeting thrombospondin expression to inhibit immune checkpoint signals such as CD36 and CD47.
Explore Vigeo's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.